



(51) International Patent Classification:

A61K 35/74 (2015.01) A61K 39/00 (2006.01)
A61K 35/744 (2015.01) C12N 15/62 (2006.01)
A61K 38/00 (2006.01) C12N 15/74 (2006.01)

(21) International Application Number:

PCT/US2021/065011

(22) International Filing Date:

22 December 2021 (22.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/130,354 23 December 2020 (23.12.2020) US
63/130,356 23 December 2020 (23.12.2020) US
63/150,013 16 February 2021 (16.02.2021) US

(71) Applicants: **CHAN ZUCKERBERG BIOHUB, INC.**
[US/US]; 499 Illinois Street, San Francisco, California
94158 (US). **THE BOARD OF TRUSTEES OF THE LE-**
LAND STANFORD JUNIOR UNIVERSITY [US/US];

Office of the General Counsel, Building 170, 3rd Floor,
Main Quad, Stanford, California 94605-2038 (US).

(72) Inventors: **FISCHBACH, Michael A.**; c/o The Board of
Trustees of the Leland Stanford Junior University, Office of
the General Counsel, Bldg. 170, Main Quad, Stanford, Cali-
fornia 94305 (US). **NAGASHIMA, Kazuki**; c/o The Board
of Trustees of the Leland Stanford Junior University, Office
of the General Counsel, Bldg. 170, Main Quad, Stanford,
California 94305 (US). **CHEN, Yiyin E.**; c/o The Board of
Trustees of the Leland Stanford Junior University, Office of
the General Counsel, Bldg. 170, Main Quad, Stanford, Cal-
ifornia 94305 (US). **BOUSBAINE, Djenet**; c/o The Board
of Trustees of the Leland Stanford Junior University, Office
of the General Counsel, Bldg. 170, Main Quad, Stanford,
California 94305 (US).

(74) Agent: **MING-LUM, Andrew N.**; Goodwin Procter LLP,
100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

(54) Title: BACTERIA-ENGINEERED TO ELICIT ANTIGEN-SPECIFIC T CELLS




FIG. 24A

(57) Abstract: Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a non-native antigen, or are surface-labeled with a non-native antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the non-native antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat an infectious disease or proliferative disease in a subject in need thereof.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))